TW202203910A - 檸檬酸鐵用於製備治療慢性腎病患者之貧血的藥劑之用途 - Google Patents

檸檬酸鐵用於製備治療慢性腎病患者之貧血的藥劑之用途 Download PDF

Info

Publication number
TW202203910A
TW202203910A TW110136784A TW110136784A TW202203910A TW 202203910 A TW202203910 A TW 202203910A TW 110136784 A TW110136784 A TW 110136784A TW 110136784 A TW110136784 A TW 110136784A TW 202203910 A TW202203910 A TW 202203910A
Authority
TW
Taiwan
Prior art keywords
ferric citrate
iron
patient
average
ckd
Prior art date
Application number
TW110136784A
Other languages
English (en)
Chinese (zh)
Inventor
安立奎 波拉多蘇
榮恩 班瑟爾
詹姆士 F 三世 奧利維羅
Original Assignee
凱克斯生物製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 凱克斯生物製藥公司 filed Critical 凱克斯生物製藥公司
Publication of TW202203910A publication Critical patent/TW202203910A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW110136784A 2013-11-04 2014-11-04 檸檬酸鐵用於製備治療慢性腎病患者之貧血的藥劑之用途 TW202203910A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
US61/899,866 2013-11-04

Publications (1)

Publication Number Publication Date
TW202203910A true TW202203910A (zh) 2022-02-01

Family

ID=53005244

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110136784A TW202203910A (zh) 2013-11-04 2014-11-04 檸檬酸鐵用於製備治療慢性腎病患者之貧血的藥劑之用途
TW103138244A TWI744215B (zh) 2013-11-04 2014-11-04 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW103138244A TWI744215B (zh) 2013-11-04 2014-11-04 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途

Country Status (15)

Country Link
US (3) US20160256486A1 (https=)
EP (2) EP3747432A1 (https=)
JP (3) JP2016535780A (https=)
KR (1) KR102392441B1 (https=)
CN (1) CN105873583A (https=)
AU (1) AU2014341975A1 (https=)
BR (1) BR112016009901A8 (https=)
CA (1) CA2928200A1 (https=)
EA (1) EA201690926A1 (https=)
HK (1) HK1223031A1 (https=)
IL (1) IL245317A0 (https=)
MX (1) MX2016005734A (https=)
SG (1) SG11201603091QA (https=)
TW (2) TW202203910A (https=)
WO (1) WO2015066593A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938585A (zh) 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
JP2022505697A (ja) 2018-10-29 2022-01-14 ファーマコスモス ホールディング エー/エス カルボキシマルトース第二鉄による鉄欠乏症の治療
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
CN117999069A (zh) * 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (https=) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
EP3066923B1 (en) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
KR20080094013A (ko) * 2006-01-30 2008-10-22 글로보아시아 엘엘씨 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법
CN108938585A (zh) * 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
EP2590655B1 (en) * 2010-07-07 2015-06-24 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
TWI744215B (zh) 2021-11-01
JP2016535780A (ja) 2016-11-17
JP2021073230A (ja) 2021-05-13
SG11201603091QA (en) 2016-05-30
IL245317A0 (en) 2016-06-30
US20160256486A1 (en) 2016-09-08
HK1223031A1 (zh) 2017-07-21
JP6828100B2 (ja) 2021-02-10
MX2016005734A (es) 2016-11-08
AU2014341975A1 (en) 2016-05-19
WO2015066593A1 (en) 2015-05-07
CA2928200A1 (en) 2015-05-07
KR20160096597A (ko) 2016-08-16
EP3065734A1 (en) 2016-09-14
JP2019206562A (ja) 2019-12-05
BR112016009901A8 (pt) 2020-04-14
KR102392441B1 (ko) 2022-05-02
EP3065734A4 (en) 2017-05-17
CN105873583A (zh) 2016-08-17
TW201609088A (zh) 2016-03-16
US20190307791A1 (en) 2019-10-10
US20250360167A1 (en) 2025-11-27
EA201690926A1 (ru) 2016-09-30
EP3747432A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
KR102150135B1 (ko) 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도
US20250360167A1 (en) Use of ferric citrate in the treatment of and the reduction of mortality and morbidity related to adverse cardiac events in chronic kidney disease patients
DK1978807T3 (en) A method for treating chronic kidney disease
US20180071243A1 (en) Use of ferric citrate in the treatment of iron-deficiency anemia
JP2019501184A (ja) 鉄化合物及びシトレート化合物を用いる併用療法
CN107106601A (zh) 用于治疗或预防接受了胃旁路手术的患者的维生素和矿物质缺乏的药物组合物
Okada Long-term follow-up of patients treated with a combination of continuous ambulatory peritoneal dialysis and hemodialysis
US20240041816A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
US20190269645A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1210013B (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
TW202547454A (zh) 治療前的尿白蛋白濃度在特定範圍之慢性腎臟病的治療用醫藥組成物